Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute (NKI)/Antoni van Leeuwenhoek Hospital in Amsterdam where it had access to the world's largest frozen tumour bank.
Agendia, a US and Netherlands-based personalized medicine company for treating breast cancer spun out off of the Netherlands Cancer Institute, has raised $65m in its series F round from a consortium led by the Debiopharm Group, a Switzerland-based drugs company. The syndicate was joined by several new international investors including Korys, the Colruyt’s family office,…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
